Peter W Hunt

List of Publications by Year
in descending order

296 papers	23,115 citations	9264 74 h-index	9861 141 g-index
307 all docs	307 docs citations	307 times ranked	20286 citing authors

#	Article	IF	Citations
1	The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation. Science, 2010, 330, 1551-1557.	12.6	1,054
2	Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature, 2014, 505, 509-514.	27.8	931
3	T Cell Activation Is Associated with Lower CD4+T Cell Gains in Human Immunodeficiency Virusâ€"Infected Patients with Sustained Viral Suppression during Antiretroviral Therapy. Journal of Infectious Diseases, 2003, 187, 1534-1543.	4.0	786
4	Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood, 2004, 104, 942-947.	1.4	688
5	Relationship between T Cell Activation and CD4⁺T Cell Count in HIVâ€Seropositive Individuals with Undetectable Plasma HIV RNA Levels in the Absence of Therapy. Journal of Infectious Diseases, 2008, 197, 126-133.	4.0	579
6	Dysbiosis of the Gut Microbiota Is Associated with HIV Disease Progression and Tryptophan Catabolism. Science Translational Medicine, 2013, 5, 193ra91.	12.4	578
7	Plasma Levels of Bacterial DNA Correlate with Immune Activation and the Magnitude of Immune Restoration in Persons with Antiretroviralâ€Treated HIV Infection. Journal of Infectious Diseases, 2009, 199, 1177-1185.	4.0	527
8	Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies. PLoS Pathogens, 2013, 9, e1003174.	4.7	524
9	HIV-Infected Individuals with Low CD4/CD8 Ratio despite Effective Antiretroviral Therapy Exhibit Altered T Cell Subsets, Heightened CD8+ T Cell Activation, and Increased Risk of Non-AIDS Morbidity and Mortality. PLoS Pathogens, 2014, 10, e1004078.	4.7	495
10	Soluble Markers of Inflammation and Coagulation but Not T-Cell Activation Predict Nonâ€"AIDS-Defining Morbid Events During Suppressive Antiretroviral Treatment. Journal of Infectious Diseases, 2014, 210, 1248-1259.	4.0	464
11	Tryptophan Catabolism by Indoleamine 2,3-Dioxygenase 1 Alters the Balance of T _H 17 to Regulatory T Cells in HIV Disease. Science Translational Medicine, 2010, 2, 32ra36.	12.4	454
12	Gut Epithelial Barrier Dysfunction and Innate Immune Activation Predict Mortality in Treated HIV Infection. Journal of Infectious Diseases, 2014, 210, 1228-1238.	4.0	395
13	Activation, exhaustion, and persistent decline of the antimicrobial MR1-restricted MAIT-cell population in chronic HIV-1 infection. Blood, 2013, 121, 1124-1135.	1.4	347
14	HIV and Inflammation: Mechanisms and Consequences. Current HIV/AIDS Reports, 2012, 9, 139-147.	3.1	333
15	Altered Virome and Bacterial Microbiome in Human Immunodeficiency Virus-Associated Acquired Immunodeficiency Syndrome. Cell Host and Microbe, 2016, 19, 311-322.	11.0	330
16	Incomplete Peripheral CD4⁺Cell Count Restoration in HIVâ€Infected Patients Receiving Longâ€Term Antiretroviral Treatment. Clinical Infectious Diseases, 2009, 48, 787-794.	5.8	329
17	Differential microRNA regulation of HLA-C expression and its association with HIV control. Nature, 2011, 472, 495-498.	27.8	328
18	Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. Aids, 2009, 23, 1059-1067.	2.2	324

#	Article	IF	Citations
19	Valganciclovir Reduces T Cell Activation in HIV-Infected Individuals With Incomplete CD4+ T Cell Recovery on Antiretroviral Therapy. Journal of Infectious Diseases, 2011, 203, 1474-1483.	4.0	308
20	Residual Immune Dysregulation Syndrome in Treated HIV infection. Advances in Immunology, 2013, 119, 51-83.	2.2	295
21	Antiretroviral Therapy Initiated Within 6 Months of HIV Infection Is Associated With Lower T-Cell Activation and Smaller HIV Reservoir Size. Journal of Infectious Diseases, 2013, 208, 1202-1211.	4.0	285
22	T Cell Activation and Senescence Predict Subclinical Carotid Artery Disease in HIV-Infected Women. Journal of Infectious Diseases, 2011, 203, 452-463.	4.0	281
23	The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4987-96.	7.1	260
24	Food insecurity, depression and the modifying role of social support among people living with HIV/AIDS in rural Uganda. Social Science and Medicine, 2012, 74, 2012-2019.	3.8	253
25	Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. Aids, 2006, 20, 2275-2283.	2.2	239
26	Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. Aids, 2003, 17, 1907-1915.	2.2	229
27	Immunologic Basis of Cardiovascular Disease in HIV-Infected Adults. Journal of Infectious Diseases, 2012, 205, S375-S382.	4.0	228
28	Cell-Based Measures of Viral Persistence Are Associated With Immune Activation and Programmed Cell Death Protein 1 (PD-1)â€“Expressing CD4+ T cells. Journal of Infectious Diseases, 2013, 208, 50-56.	4.0	227
29	Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood, 2009, 113, 3978-3989.	1.4	198
30	Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. Aids, 2011, 25, 2123-2131.	2.2	195
31	Immunologic Biomarkers, Morbidity, and Mortality in Treated HIV Infection. Journal of Infectious Diseases, 2016, 214, S44-S50.	4.0	195
32	Real-Time Adherence Monitoring for HIV Antiretroviral Therapy. AIDS and Behavior, 2010, 14, 1340-1346.	2.7	192
33	Evidence for Persistent Low-Level Viremia in Individuals Who Control Human Immunodeficiency Virus in the Absence of Antiretroviral Therapy. Journal of Virology, 2009, 83, 329-335.	3.4	191
34	Cytomegalovirus-Specific T Cells Persist at Very High Levels during Long-Term Antiretroviral Treatment of HIV Disease. PLoS ONE, 2010, 5, e8886.	2.5	176
35	A Randomized, Controlled Trial of Raltegravir Intensification in Antiretroviral-treated, HIV-infected Patients with a Suboptimal CD4+ T Cell Response. Journal of Infectious Diseases, 2011, 203, 960-968.	4.0	176
36	Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Journal of Infectious Diseases, 2021, 224, 1839-1848.	4.0	176

#	Article	IF	Citations
37	Impact of HIV Infection on Diastolic Function and Left Ventricular Mass. Circulation: Heart Failure, 2010, 3, 132-139.	3.9	163
38	Gut epithelial barrier and systemic inflammation during chronic HIV infection. Aids, 2015, 29, 43-51.	2.2	156
39	Food insecurity is associated with morbidity and patterns of healthcare utilization among HIV-infected individuals in a resource-poor setting. Aids, 2012, 26, 67-75.	2.2	146
40	HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. Blood, 2011, 117, 5142-5151.	1.4	140
41	Old age and anti-cytomegalovirus immunity are associated with altered T-cell reconstitution in HIV-1-infected patients. Aids, 2011, 25, 1813-1822.	2.2	140
42	Differential decay of intact and defective proviral DNA in HIV-1â€“infected individuals on suppressive antiretroviral therapy. JCI Insight, 2020, 5, .	5.0	140
43	Longitudinal Genetic Characterization Reveals That Cell Proliferation Maintains a Persistent HIV Type 1 DNA Pool During Effective HIV Therapy. Journal of Infectious Diseases, 2015, 212, 596-607.	4.0	138
44	Prevalence of CXCR4 Tropism among Antiretroviralâ€Treated HIVâ€1â€“Infected Patients with Detectable Viremia. Journal of Infectious Diseases, 2006, 194, 926-930.	4.0	137
45	Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. Aids, 2009, 23, 2021-2027.	2.2	137
46	Longitudinal assessment of associations between food insecurity, antiretroviral adherence and HIV treatment outcomes in rural Uganda. Aids, 2014, 28, 115-120.	2.2	137
47	Internalized Stigma, Social Distance, and Disclosure of HIV Seropositivity in Rural Uganda. Annals of Behavioral Medicine, 2013, 46, 285-294.	2.9	129
48	Neutralizing Antibody Responses against Autologous and Heterologous Viruses in Acute versus Chronic Human Immunodeficiency Virus (HIV) Infection: Evidence for a Constraint on the Ability of HIV To Completely Evade Neutralizing Antibody Responses. Journal of Virology, 2006, 80, 6155-6164.	3.4	127
49	A Low T Regulatory Cell Response May Contribute to Both Viral Control and Generalized Immune Activation in HIV Controllers. PLoS ONE, 2011, 6, e15924.	2.5	122
50	T cell activation predicts carotid artery stiffness among HIV-infected women. Atherosclerosis, 2011, 217, 207-213.	0.8	117
51	The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. Blood, 2013, 121, 4635-4646.	1.4	117
52	CD8 T-Cell Expansion and Inflammation Linked to CMV Coinfection in ART-treated HIV Infection. Clinical Infectious Diseases, 2016, 62, 392-396.	5.8	114
53	Genetic interplay betweenHLA-CandMIR148Ain HIV control and Crohn disease. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 20705-20710.	7.1	109
54	Incidence and Timing of Cancer in HIV-Infected Individuals Following Initiation of Combination Antiretroviral Therapy. Clinical Infectious Diseases, 2013, 57, 756-764.	5.8	107

#	Article	IF	Citations
55	The Dynamic Relationship Between Social Support and HIV-Related Stigma in Rural Uganda. Annals of Behavioral Medicine, 2014, 48, 26-37.	2.9	104
56	HIV Controllers with HLA-DRB1*13 and HLA-DQB1*06 Alleles Have Strong, Polyfunctional Mucosal CD4⁺T-Cell Responses. Journal of Virology, 2010, 84, 11020-11029.	3.4	102
57	Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. Aids, 2004, 18, 981-989.	2.2	101
58	The Kynurenine Pathway of Tryptophan Catabolism, CD4+ T-Cell Recovery, and Mortality Among HIV-Infected Ugandans Initiating Antiretroviral Therapy. Journal of Infectious Diseases, 2014, 210, 383-391.	4.0	101
59	Programmed death-1 expression on CD4+ and CD8+ T cells in treated and untreated HIV disease. Aids, 2014, 28, 1749-1758.	2.2	101
60	Cytomegalovirus Immunoglobulin G Antibody Is Associated With Subclinical Carotid Artery Disease Among HIV-Infected Women. Journal of Infectious Diseases, 2012, 205, 1788-1796.	4.0	100
61	HIV-infected persons continue to lose kidney function despite successful antiretroviral therapy. Aids, 2009, 23, 2143-2149.	2.2	99
62	Increased Frequency of Regulatory T Cells Accompanies Increased Immune Activation in Rectal Mucosae of HIV-Positive Noncontrollers. Journal of Virology, 2011, 85, 11422-11434.	3.4	98
63	IL-15 promotes activation and expansion of CD8+ T cells in HIV-1 infection. Journal of Clinical Investigation, 2016, 126, 2745-2756.	8.2	97
64	Disease drivers of aging. Annals of the New York Academy of Sciences, 2016, 1386, 45-68.	3.8	97
65	Human Immunodeficiency Virus Persistence and T-Cell Activation in Blood, Rectal, and Lymph Node Tissue in Human Immunodeficiency Virusâ€"Infected Individuals Receiving Suppressive Antiretroviral Therapy. Journal of Infectious Diseases, 2017, 215, 911-919.	4.0	95
66	Prospective Antiretroviral Treatment of Asymptomatic, HIV-1 Infected Controllers. PLoS Pathogens, 2013, 9, e1003691.	4.7	94
67	AIDS Alters the Commensal Plasma Virome. Journal of Virology, 2013, 87, 10912-10915.	3.4	89
68	Comparison of Self-Reported Alcohol Consumption to Phosphatidylethanol Measurement among HIV-Infected Patients Initiating Antiretroviral Treatment in Southwestern Uganda. PLoS ONE, 2014, 9, e113152.	2.5	89
69	Rate of Viral Evolution and Risk of Losing Future Drug Options in Heavily Pretreated, HIV-Infected Patients Who Continue to Receive a Stable, Partially Suppressive Treatment Regimen. Clinical Infectious Diseases, 2006, 43, 1329-1336.	5.8	87
70	Carotid Intimaâ€Media Thickness Progression in HIVâ€Infected Adults Occurs Preferentially at the Carotid Bifurcation and Is Predicted by Inflammation. Journal of the American Heart Association, 2012, 1, .	3.7	87
71	Impact of HIV on CD8+ T Cell CD57 Expression Is Distinct from That of CMV and Aging. PLoS ONE, 2014, 9, e89444.	2.5	85
72	Heavy Cannabis Use Associated With Reduction in Activated and Inflammatory Immune Cell Frequencies in Antiretroviral Therapyâ€"Treated Human Immunodeficiency Virusâ€"Infected Individuals. Clinical Infectious Diseases, 2018, 66, 1872-1882.	5.8	85

#	Article	IF	Citations
73	A role for cytomegalovirus-specific CD4+CX3CR1+ T cells and cytomegalovirus-induced T-cell immunopathology in HIV-associated atherosclerosis. Aids, 2012, 26, 805-814.	2.2	83
74	GPS-measured distance to clinic, but not self-reported transportation factors, are associated with missed HIV clinic visits in rural Uganda. Aids, 2013, 27, 1503-1508.	2.2	83
75	Limited HIV Infection of Central Memory and Stem Cell Memory CD4+ T Cells Is Associated with Lack of Progression in Viremic Individuals. PLoS Pathogens, 2014, 10, e1004345.	4.7	76
76	Gut and blood differ in constitutive blocks to HIV transcription, suggesting tissue-specific differences in the mechanisms that govern HIV latency. PLoS Pathogens, 2018, 14, e1007357.	4.7	76
77	How Does Antiretroviral Treatment Attenuate the Stigma of HIV? Evidence from a Cohort Study in Rural Uganda. AIDS and Behavior, 2013, 17, 2725-2731.	2.7	75
78	Reversal of the Kynurenine Pathway of Tryptophan Catabolism May Improve Depression in ART-Treated HIV-Infected Ugandans. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 456-462.	2.1	72
79	Replication of CMV in the gut of HIV-infected individuals and epithelial barrier dysfunction. PLoS Pathogens, 2017, 13, e1006202.	4.7	71
80	Persistent Immune Activation and Carotid Atherosclerosis in HIV-Infected Ugandans Receiving Antiretroviral Therapy. Journal of Infectious Diseases, 2016, 213, 370-378.	4.0	69
81	Ability of HIV-1 Nef to downregulate CD4 and HLA class I differs among viral subtypes. Retrovirology, 2013, 10, 100.	2.0	68
82	A simple LCâ€“MS/MS method for determination of kynurenine and tryptophan concentrations in human plasma from HIV-infected patients. Bioanalysis, 2013, 5, 1397-1407.	1.5	66
83	Persistent HIV-related stigma in rural Uganda during a period of increasing HIV incidence despite treatment expansion. Aids, 2015, 29, 83-90.	2.2	63
84	Phenotypic analysis of the unstimulated in vivo HIV CD4 T cell reservoir. ELife, 2020, 9, .	6.0	63
85	Th17, gut, and HIV: therapeutic implications. Current Opinion in HIV and AIDS, 2010, 5, 189-193.	3.8	62
86	Realtime adherence monitoring of antiretroviral therapy among hiv-infected adults and children in rural uganda. Aids, 2013, 27, 2166-2168.	2.2	62
87	A comparison of methods for measuring rectal HIV levels suggests that HIV DNA resides in cells other than CD4+ T cells, including myeloid cells. Aids, 2014, 28, 439-442.	2.2	62
88	Role of immune activation in HIV pathogenesis. Current HIV/AIDS Reports, 2007, 4, 42-47.	3.1	61
89	Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals. Aids, 2010, 24, 2535-2539.	2.2	61
90	Immunodominant HIV-Specific CD8⁺T-Cell Responses Are Common to Blood and Gastrointestinal Mucosa, and Gag-Specific Responses Dominate in Rectal Mucosa of HIV Controllers. Journal of Virology, 2010, 84, 10354-10365.	3.4	61

#	Article	IF	Citations
91	Types of Myocardial Infarction Among Human Immunodeficiency Virusâ€"Infected Individuals in the United States. JAMA Cardiology, 2017, 2, 260.	6.1	61
92	HIV-1-induced cytokines deplete homeostatic innate lymphoid cells and expand TCF7-dependent memory NK cells. Nature Immunology, 2020, 21, 274-286.	14.5	60
93	Evidence for the Reliability and Validity of the Internalized AIDS-Related Stigma Scale in Rural Uganda. AIDS and Behavior, 2013, 17, 427-433.	2.7	59
94	Duration of Antiretroviral Therapy Adherence Interruption Is Associated With Risk of Virologic Rebound as Determined by Real-Time Adherence Monitoring in Rural Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 70, 386-392.	2.1	58
95	Role of immune activation in progression to AIDS. Current Opinion in HIV and AIDS, 2016, 11, 131-137.	3.8	58
96	A Randomized Placebo Controlled Trial of Aspirin Effects on Immune Activation in Chronically Human Immunodeficiency Virus-Infected Adults on Virologically Suppressive Antiretroviral Therapy. Open Forum Infectious Diseases, 2017, 4, ofw278.	0.9	58
97	Impact of early cART in the gut during acute HIV infection. JCI Insight, 2016, 1, .	5.0	56
98	Limited engraftment of donor microbiome via one-time fecal microbial transplantation in treated HIV-infected individuals. Gut Microbes, 2017, 8, 440-450.	9.8	56
99	The Immunologic Effects of Mesalamine in Treated HIV-Infected Individuals with Incomplete CD4+ T Cell Recovery: A Randomized Crossover Trial. PLoS ONE, 2014, 9, e116306.	2.5	56
100	Depression During Pregnancy and the Postpartum Among HIV-Infected Women on Antiretroviral Therapy in Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, S179-S187.	2.1	53
101	The CD8 ⁺ Memory Stem T Cell (T _{SCM}) Subset Is Associated with Improved Prognosis in Chronic HIV-1 Infection. Journal of Virology, 2014, 88, 13836-13844.	3.4	53
102	Low Proportions of CD28â˜' CD8+ T cells Expressing CD57 Can Be Reversed by Early ART Initiation and Predict Mortality in Treated HIV Infection. Journal of Infectious Diseases, 2014, 210, 374-382.	4.0	53
103	Antiretroviral Treatment Effect on Immune Activation Reduces Cerebrospinal Fluid HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 47, 544-552.	2.1	52
104	Immunosenescence is associated with presence of Kaposi's sarcoma in antiretroviral treated HIV infection. Aids, 2013, 27, 1735-1742.	2.2	52
105	The HIV-1 proviral landscape reveals that Nef contributes to HIV-1 persistence in effector memory CD4+ T cells. Journal of Clinical Investigation, 2022, 132, .	8.2	52
106	Incidence and predictors of hypertension in adults with HIV-initiating antiretroviral therapy in south-western Uganda. Journal of Hypertension, 2015, 33, 2039-2045.	0.5	51
107	Incidence and Predictors of Pregnancy among a Cohort of HIV-Positive Women Initiating Antiretroviral Therapy in Mbarara, Uganda. PLoS ONE, 2013, 8, e63411.	2.5	51
108	CD4/CD8 Ratio and KT Ratio Predict Yellow Fever Vaccine Immunogenicity in HIV-Infected Patients. PLoS Neglected Tropical Diseases, 2016, 10, e0005219.	3.0	50

#	Article	IF	Citations
109	Sexual Relationship Power and Depression among HIV-Infected Women in Rural Uganda. PLoS ONE, 2012, 7, e49821.	2.5	50
110	Lymphoid Fibrosis Occurs in Long-Term Nonprogressors and Persists With Antiretroviral Therapy but May Be Reversible With Curative Interventions. Journal of Infectious Diseases, 2015, 211, 1068-1075.	4.0	49
111	Epigenetic mechanisms, T-cell activation, andCCR5genetics interact to regulate T-cell expression of CCR5, the major HIV-1 coreceptor. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E4762-71.	7.1	48
112	Association of Vitamin D Insufficiency with Carotid Intima-Media Thickness in HIV-Infected Persons. Clinical Infectious Diseases, 2011, 52, 941-944.	5.8	44
113	Comparison of HIV DNA and RNA in gut-associated lymphoid tissue of HIV-infected controllers and noncontrollers. Aids, 2013, 27, 2255-2260.	2.2	44
114	Trends in the clinical characteristics of HIV-infected patients initiating antiretroviral therapy in Kenya, Uganda and Tanzania between 2002 and 2009. Journal of the International AIDS Society, 2011, 14, 46.	3.0	43
115	Higher Baseline CD4 Cell Count Predicts Treatment Interruptions and Persistent Viremia in Patients Initiating ARVs in Rural Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 317-321.	2.1	43
116	TCF-1 regulates HIV-specific CD8+ T cell expansion capacity. JCI Insight, 2021, 6, .	5.0	43
117	HIV and aging. Current Opinion in HIV and AIDS, 2014, 9, 302-308.	3.8	42
118	Pathogenesis of Aging and Age-related Comorbidities in People with HIV: Highlights from the HIV ACTION Workshop. Pathogens and Immunity, 2020, 5, 143.	3.1	42
119	Interruption of Enfuvirtide in HIVâ€1â€“Infected Adults with Incomplete Viral Suppression on an Enfuvirtideâ€Based Regimen. Journal of Infectious Diseases, 2007, 195, 387-391.	4.0	41
120	Stimulant Use and Viral Suppression in the Era of Universal Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 89-93.	2.1	41
121	Prospective Study of the Mental Health Consequences of Sexual Violence Among Women Living With HIV in Rural Uganda. Journal of Interpersonal Violence, 2016, 31, 1531-1553.	2.0	40
122	Increased Systemic Inflammation and Gut Permeability Among Women With Treated HIV Infection in Rural Uganda. Journal of Infectious Diseases, 2018, 218, 922-926.	4.0	40
123	HIV Viremia and Incidence of Non-Hodgkin Lymphoma in Patients Successfully Treated With Antiretroviral Therapy. Clinical Infectious Diseases, 2014, 58, 1599-1606.	5.8	39
124	Expansion of CD8+ T cells lacking Sema4D/CD100 during HIV-1 infection identifies a subset of T cells with decreased functional capacity. Blood, 2012, 119, 745-755.	1.4	38
125	Detection of HIV-1-specific gastrointestinal tissue resident CD8+ T-cells in chronic infection. Mucosal Immunology, 2018, 11, 909-920.	6.0	38
126	Correlating cellular and molecular signatures of mucosal immunity that distinguish HIV controllers from noncontrollers. Blood, 2010, 115, e20-e32.	1.4	36

#	Article	IF	Citations
127	Changes in Food Insecurity, Nutritional Status, and Physical Health Status After Antiretroviral Therapy Initiation in Rural Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 61, 179-186.	2.1	36
128	Age at Entry Into Care, Timing of Antiretroviral Therapy Initiation, and 10-Year Mortality Among HIV-Seropositive Adults in the United States. Clinical Infectious Diseases, 2015, 61, 1189-1195.	5.8	36
129	Substance-associated elevations in monocyte activation among methamphetamine users with treated HIV infection. Aids, 2018, 32, 767-771.	2.2	36
130	Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection. Journal of Infectious Diseases, 2018, 218, 1394-1403.	4.0	36
131	Increased mucosal neutrophil survival is associated with altered microbiota in HIV infection. PLoS Pathogens, 2019, 15, e1007672.	4.7	36
132	The independent effect of drug resistance on T cell activation in HIV infection. Aids, 2006, 20, 691-699.	2.2	35
133	Blunted Response to Combination Antiretroviral Therapy in HIV Elite Controllers: An International HIV Controller Collaboration. PLoS ONE, 2014, 9, e85516.	2.5	34
134	Subtype-Specific Differences in Gag-Protease-Driven Replication Capacity Are Consistent with Intersubtype Differences in HIV-1 Disease Progression. Journal of Virology, 2017, 91, .	3.4	34
135	HIV-Specific CD4+ T Cells May Contribute to Viral Persistence in HIV Controllers. Clinical Infectious Diseases, 2011, 52, 681-687.	5.8	33
136	Ideal Cardiovascular Health and Carotid Atherosclerosis in a Mixed Cohort of HIV-Infected and Uninfected Ugandans. AIDS Research and Human Retroviruses, 2017, 33, 49-56.	1.1	33
137	Immunologic Pathways That Predict Mortality in HIV-Infected Ugandans Initiating Antiretroviral Therapy. Journal of Infectious Diseases, 2017, 215, 1270-1274.	4.0	33
138	CD28-Negative CD4+ and CD8+ T Cells in Antiretroviral Therapyâ€“Naive HIV-Infected Adults Enrolled in Adult Clinical Trials Group Studies. Journal of Infectious Diseases, 2012, 205, 1730-1738.	4.0	31
139	Real-time electronic adherence monitoring plus follow-up improves adherence compared with standard electronic adherence monitoring. Aids, 2017, 31, 169-171.	2.2	31
140	Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus. Clinical Infectious Diseases, 2022, 74, 95-104.	5.8	31
141	Brief Report: Higher ART Adherence Is Associated With Lower Systemic Inflammation in Treatment-Naive Ugandans Who Achieve Virologic Suppression. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 507-513.	2.1	30
142	CD8+ T-Cell Activation in HIV-1â€“Infected Patients Experiencing Transient Low-level Viremia During Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 101-104.	2.1	29
143	Factors Associated With CD8+ T-Cell Activation in HIV-1â€“Infected Patients on Long-term Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, 153-160.	2.1	29
144	Changes in Inflammation but Not in T-Cell Activation Precede Non-AIDS-Defining Events in a Case-Control Study of Patients on Long-term Antiretroviral Therapy. Journal of Infectious Diseases, 2018, 218, 239-248.	4.0	29

#	Article	IF	Citations
145	Differential Expression of CD8+ T Cell Cytotoxic Effector Molecules in Blood and Gastrointestinal Mucosa in HIV-1 Infection. Journal of Immunology, 2018, 200, 1876-1888.	0.8	28
146	Presence of asymptomatic cytomegalovirus and Epstein–Barr virus DNA in blood of persons with HIV starting antiretroviral therapy is associated with non-AIDS clinical events. Aids, 2020, 34, 849-857.	2.2	27
147	Natural Control of HIVâ€1 Replication and Longâ€Term Nonprogression: Overlapping but Distinct Phenotypes. Journal of Infectious Diseases, 2009, 200, 1636-1638.	4.0	26
148	Prevalence and Virologic Consequences of Transmitted HIV-1 Drug Resistance in Uganda. AIDS Research and Human Retroviruses, 2014, 30, 896-906.	1.1	26
149	Recent stimulant use and leukocyte gene expression in methamphetamine users with treated HIV infection. Brain, Behavior, and Immunity, 2018, 71, 108-115.	4.1	26
150	Prevalence and correlates of physical and sexual intimate partner violence among women living with HIV in Uganda. PLoS ONE, 2018, 13, e0202992.	2.5	26
151	Cerebrospinal fluid in HIV-1 systemic viral controllers: absence of HIV-1 RNA and intrathecal inflammation. Aids, 2010, 24, 1001-1005.	2.2	25
152	Point-of-Care C-Reactive Protein Testing to Facilitate Implementation of Isoniazid Preventive Therapy for People Living With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 551-556.	2.1	25
153	Incidence of Intermediate-stage Age-related Macular Degeneration in Patients With Acquired Immunodeficiency Syndrome. American Journal of Ophthalmology, 2017, 179, 151-158.	3.3	25
154	Relationship between CD4 T cell turnover, cellular differentiation and HIV persistence during ART. PLoS Pathogens, 2021, 17, e1009214.	4.7	25
155	Optimizing Network Connectivity for Mobile Health Technologies in sub-Saharan Africa. PLoS ONE, 2012, 7, e45643.	2.5	25
156	HIV-Infected Ugandan Women on Antiretroviral Therapy Maintain HIV-1 RNA Suppression Across Periconception, Pregnancy, and Postpartum Periods. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 399-406.	2.1	24
157	Lower Pretreatment Gut Integrity Is Independently Associated With Fat Gain on Antiretroviral Therapy. Clinical Infectious Diseases, 2019, 68, 1394-1401.	5.8	24
158	Factors Associated With Severity of COVID-19 Disease in a Multicenter Cohort of People With HIV in the United States, Marchâ€“December 2020. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, 90, 369-376.	2.1	24
159	Dissemination of Research Findings to Research Participants Living with HIV in Rural Uganda: Challenges and Rewards. PLoS Medicine, 2013, 10, e1001397.	8.4	23
160	HIV-infected women on antiretroviral treatment have increased mortality during pregnant and postpartum periods. Aids, 2013, 27, S105-S112.	2.2	23
161	Discordance Between Peripheral and Colonic Markers of Inflammation During Suppressive ART. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 133-141.	2.1	23
162	CD4+ cell count at antiretroviral therapy initiation and economic restoration in rural Uganda. Aids, 2014, 28, 1221-1226.	2.2	23

#	Article	IF	Citations
163	The Factor Structure and Presentation of Depression Among HIV-Positive Adults in Uganda. AIDS and Behavior, 2015, 19, 27-33.	2.7	23
164	HIV infection and arterial stiffness among older-adults taking antiretroviral therapy in rural Uganda. Aids, 2016, 30, 667-670.	2.2	23
165	An Optimized and Validated Method for Isolation and Characterization of Lymphocytes from HIV+ Human Gut Biopsies. AIDS Research and Human Retroviruses, 2017, 33, S-31-S-39.	1.1	23
166	Prevalence and clinical impacts of HIV-1 intersubtype recombinants in Uganda revealed by near-full-genome population and deep sequencing approaches. Aids, 2017, 31, 2345-2354.	2.2	23
167	Infection With Different HIV Subtypes Is Associated With CD4 Activation-Associated Dysfunction and Apoptosis. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 52, 548-552.	2.1	22
168	Immunologic profiles distinguish aviremic HIV-infected adults. Aids, 2016, 30, 1553-1562.	2.2	22
169	Early and Delayed Antiretroviral Therapy Results in Comparable Reductions in CD8+ T Cell Exhaustion Marker Expression. AIDS Research and Human Retroviruses, 2017, 33, 658-667.	1.1	22
170	Mortality following myocardial infarction among HIV-infected persons: the Center for AIDS Research Network Of Integrated Clinical Systems (CNICS). BMC Medicine, 2019, 17, 149.	5.5	22
171	Immune Activation While on Potent Antiretroviral Therapy Can Predict Subsequent CD4+ T-Cell Increases Through 15 Years of Treatment. HIV Clinical Trials, 2013, 14, 61-67.	2.0	21
172	Physical Activity Intensity is Associated with Symptom Distress in the CNICS Cohort. AIDS and Behavior, 2019, 23, 627-635.	2.7	21
173	Variation in HIV-1 Nef function within and among viral subtypes reveals genetically separable antagonism of SERINC3 and SERINC5. PLoS Pathogens, 2020, 16, e1008813.	4.7	20
174	Impact of Antiretroviral Therapy Duration on HIV-1 Infection of T Cells within Anatomic Sites. Journal of Virology, 2020, 94, .	3.4	20
175	Abnormal Levels of Some Biomarkers of Immune Activation Despite Very Early Treatment of Human Immunodeficiency Virus. Journal of Infectious Diseases, 2021, 223, 1621-1630.	4.0	20
176	Unhealthy Alcohol Use is Associated with Monocyte Activation Prior to Starting Antiretroviral Therapy. Alcoholism: Clinical and Experimental Research, 2015, 39, 2422-2426.	2.4	19
177	Elucidating the Burden of HIV in Tissues Using Multiplexed Immunofluorescence and In Situ Hybridization: Methods for the Single-Cell Phenotypic Characterization of Cells Harboring HIV In Situ. Journal of Histochemistry and Cytochemistry, 2018, 66, 427-446.	2.5	19
178	A hidden menace? Cytomegalovirus infection is associated with reduced cortical gray matter volume in major depressive disorder. Molecular Psychiatry, 2021, 26, 4234-4244.	7.9	19
179	Comparative Effectiveness of Fish Oil Versus Fenofibrate, Gemfibrozil, and Atorvastatin on Lowering Triglyceride Levels Among HIV-Infected Patients in Routine Clinical Care. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 64, 254-260.	2.1	18
180	The impact of age on the prognostic capacity of CD8+ T-cell activation during suppressive antiretroviral therapy. Aids, 2013, 27, 2101-2110.	2.2	18

#	Article	IF	Citations
181	The influence of partnership on contraceptive use among HIV-infected women accessing antiretroviral therapy in rural Uganda. Contraception, 2015, 92, 152-159.	1.5	18
182	D-Dimer Levels and Traditional Risk Factors Are Associated With Incident Hypertension Among HIV-Infected Individuals Initiating Antiretroviral Therapy in Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 396-402.	2.1	18
183	Brief Report: Systemic Inflammation, Immune Activation, and Impaired Lung Function Among People Living With HIV in Rural Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 543-548.	2.1	18
184	Can Biomarkers Advance HIV Research and Care in the Antiretroviral Therapy Era?. Journal of Infectious Diseases, 2018, 217, 521-528.	4.0	18
185	Depression and Suicidal Ideation Among HIV-Infected Adults Receiving Efavirenz Versus Nevirapine in Uganda. Annals of Internal Medicine, 2018, 169, 146.	3.9	18
186	Human Herpesvirus Replication and Abnormal CD8+ T Cell Activation and Low CD4+ T Cell Counts in Antiretroviral-Suppressed HIV-Infected Patients. PLoS ONE, 2009, 4, e5277.	2.5	18
187	Relationship Power and Sexual Violence Among HIV-Positive Women in Rural Uganda. AIDS and Behavior, 2016, 20, 2045-2053.	2.7	17
188	Duration of Viral Suppression and Risk of Rebound Viremia with First-Line Antiretroviral Therapy in Rural Uganda. AIDS and Behavior, 2017, 21, 1735-1740.	2.7	17
189	Genotypic and Mechanistic Characterization of Subtype-Specific HIV Adaptation to Host Cellular Immunity. Journal of Virology, 2019, 93, .	3.4	17
190	Antiretroviral Therapy Concentrations Differ in Gut vs. Lymph Node Tissues and Are Associated With HIV Viral Transcription by a Novel RT-ddPCR Assay. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 83, 530-537.	2.1	17
191	Immuneâ€Based Therapy for HIV Infection: Are Acute and Chronic HIV Infection Different Diseases?. Journal of Infectious Diseases, 2006, 194, 1632-1634.	4.0	16
192	Disinhibition in Risky Sexual Behavior in Men, but Not Women, during Four Years of Antiretroviral Therapy in Rural, Southwestern Uganda. PLoS ONE, 2013, 8, e69634.	2.5	16
193	Relationship of immunologic response to antiretroviral therapy with non-AIDS defining cancer incidence. Aids, 2014, 28, 979-987.	2.2	16
194	Treatment as long-term prevention. Aids, 2014, 28, 267-271.	2.2	16
195	Replicable association between human cytomegalovirus infection and reduced white matter fractional anisotropy in major depressive disorder. Neuropsychopharmacology, 2021, 46, 928-938.	5.4	16
196	Tobacco Use Among Adults Initiating Treatment for HIV Infection in Rural Uganda. AIDS and Behavior, 2014, 18, 1381-1389.	2.7	15
197	Distribution and Performance of Cardiovascular Risk Scores in a Mixed Population of HIV-Infected and Community-Based HIV-Uninfected Individuals in Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 458-464.	2.1	15
198	Carnitine Is Associated With Atherosclerotic Risk and Myocardial Infarction in HIVâ€Infected Adults. Journal of the American Heart Association, 2019, 8, e011037.	3.7	15

#	Article	IF	Citations
199	Changes in the Fungal Marker Î²-D-Glucan After Antiretroviral Therapy and Association With Adiposity. Open Forum Infectious Diseases, 2019, 6, ofz434.	0.9	15
200	Markers of inflammation and immune activation are associated with lung function in a multi-center cohort of persons with HIV. Aids, 2021, 35, 1031-1040.	2.2	15
201	CD32-RNA Co-localizes with HIV-RNA in CD3+ Cells Found within Gut Tissues from Viremic and ART-Suppressed Individuals. Pathogens and Immunity, 2019, 4, 147.	3.1	15
202	Sexual Relationship Power and Malnutrition Among HIV-Positive Women in Rural Uganda. AIDS and Behavior, 2012, 16, 1542-1548.	2.7	14
203	Brief Report: Appraising Viral Load Thresholds and Adherence Support Recommendations in the World Health Organization Guidelines for Detection and Management of Virologic Failure. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 183-187.	2.1	14
204	Some Aspects of CD8+ T-Cell Exhaustion Are Associated With Altered T-Cell Mitochondrial Features and ROS Content in HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, 211-219.	2.1	14
205	Antiretroviral Therapy Adherence Interruptions Are Associated With Systemic Inflammation Among Ugandans Who Achieved Viral Suppression. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, 386-391.	2.1	14
206	Mechanistic differences underlying HIV latency in the gut and blood contribute to differential responses to latency-reversing agents. Aids, 2020, 34, 2013-2024.	2.2	14
207	Gag p24 Is a Marker of Human Immunodeficiency Virus Expression in Tissues and Correlates With Immune Response. Journal of Infectious Diseases, 2021, 224, 1593-1598.	4.0	14
208	Clinical consequences of asymptomatic cytomegalovirus in treated human immunodeficency virus infection. Current Opinion in HIV and AIDS, 2021, 16, 168-176.	3.8	14
209	Lack of Evidence for mtDNA as a Biomarker of Innate Immune Activation in HIV Infection. PLoS ONE, 2012, 7, e50486.	2.5	14
210	Host genetic determinants of HIV pathogenesis: an immunologic perspective. Current Opinion in HIV and AIDS, 2008, 3, 342-348.	3.8	13
211	Regional Anthropometry Changes in Antiretroviral-NaÃ¯ve Persons Initiating a Zidovudine-Containing Regimen in Mbarara, Uganda. AIDS Research and Human Retroviruses, 2011, 27, 785-791.	1.1	13
212	Short Communication: HIV+ Viremic Slow Progressors Maintain Low Regulatory T Cell Numbers in Rectal Mucosa but Exhibit High T Cell Activation. AIDS Research and Human Retroviruses, 2013, 29, 172-177.	1.1	13
213	The Kynurenine Pathway of Tryptophan Catabolism and AIDS-Associated Kaposi Sarcoma in Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 70, 296-303.	2.1	13
214	Host genetic predictors of the kynurenine pathway of tryptophan catabolism among treated HIV-infected Ugandans. Aids, 2016, 30, 1807-1815.	2.2	13
215	Very Early ART and Persistent Inflammation in Treated HIV. Clinical Infectious Diseases, 2017, 64, 132-133.	5.8	13
216	Increasing Prevalence of HIV Pretreatment Drug Resistance in Women But Not Men in Rural Uganda During 2005â€“2013. AIDS Patient Care and STDs, 2018, 32, 257-264.	2.5	13

#	Article	IF	Citations
217	No Association Found Between Traditional Healer Use and Delayed Antiretroviral Initiation in Rural Uganda. AIDS and Behavior, 2013, 17, 260-265.	2.7	12
218	A20 upregulation during treated HIV disease is associated with intestinal epithelial cell recovery and function. PLoS Pathogens, 2018, 14, e1006806.	4.7	12
219	Cumulative Human Immunodeficiency Viremia, Antiretroviral Therapy, and Incident Myocardial Infarction. Epidemiology, 2019, 30, 69-74.	2.7	12
220	Participating in Human Immunodeficiency Virus Cure Research at the End of Life. Clinical Infectious Diseases, 2019, 69, 1068-1070.	5.8	12
221	Super learner analysis of realâ€time electronically monitored adherence to antiretroviral therapy under constrained optimization and comparison to nonâ€differentiated care approaches for persons living with HIV in rural Uganda. Journal of the International AIDS Society, 2020, 23, e25467.	3.0	12
222	Empiric Deworming and CD4 Count Recovery in HIV-Infected Ugandans Initiating Antiretroviral Therapy. PLoS Neglected Tropical Diseases, 2014, 8, e3036.	3.0	11
223	Declining Prevalence of Probable Depression Among Patients Presenting for Antiretroviral Therapy in Rural Uganda: The Role of Early Treatment Initiation. AIDS and Behavior, 2015, 19, 19-26.	2.7	11
224	Immune Activation and HIV-Specific CD8+ T Cells in Cerebrospinal Fluid of HIV Controllers and Noncontrollers. AIDS Research and Human Retroviruses, 2016, 32, 791-800.	1.1	11
225	Cooking fuel and respiratory symptoms among people living with HIV in rural Uganda. ERJ Open Research, 2017, 3, 00094-2016.	2.6	11
226	Kynurenine 3-Monooxygenase Inhibition during Acute Simian Immunodeficiency Virus Infection Lowers PD-1 Expression and Improves Postâ€“Combination Antiretroviral Therapy CD4+ T Cell Counts and Body Weight. Journal of Immunology, 2019, 203, 899-910.	0.8	11
227	Circulating CD30+CD4+ T Cells Increase Before Human Immunodeficiency Virus Rebound After Analytical Antiretroviral Treatment Interruption. Journal of Infectious Diseases, 2020, 221, 1146-1155.	4.0	11
228	Genetic architecture of cardiometabolic risks in people living with HIV. BMC Medicine, 2020, 18, 288.	5.5	11
229	Treated HIV Infection and Progression of Carotid Atherosclerosis in Rural Uganda: A Prospective Observational Cohort Study. Journal of the American Heart Association, 2021, 10, e019994.	3.7	11
230	Association between cytomegalovirus infection, reduced gray matter volume, and resting-state functional hypoconnectivity in major depressive disorder: a replication and extension. Translational Psychiatry, 2021, 11, 464.	4.8	11
231	HIV-1 Genomes Are Enriched in Memory CD4 ⁺ T-Cells with Short Half-Lives. MBio, 2021, 12, e0244721.	4.1	11
232	CD4+ T cell recovery during suppression of HIV replication: an international comparison of the immunological efficacy of antiretroviral therapy in North America, Asia and Africa. International Journal of Epidemiology, 2015, 44, 251-263.	1.9	10
233	p16INK4a Expression and Immunologic Aging in Chronic HIV Infection. PLoS ONE, 2016, 11, e0166759.	2.5	10
234	Soluble CD163 and Clinical Outcomes in Treated HIV Infection: Insights Into Mechanisms. Journal of Infectious Diseases, 2016, 214, 1132-1133.	4.0	10

#	Article	IF	Citations
235	Antiretroviral Treatment of Acute HIV Infection Normalizes Levels of Cerebrospinal Fluid Markers of Central Nervous System (CNS) Inflammation: A Consequence of a Reduced CNS Reservoir?. Journal of Infectious Diseases, 2019, 220, 1867-1869.	4.0	10
236	A Randomized Controlled Trial of Lisinopril to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Individuals. Pathogens and Immunity, 2017, 2, 310.	3.1	10
237	Human leukocyte antigen B*57 does not fully explain hepatitis C clearance in HIV controllers. Aids, 2013, 27, 2691-2696.	2.2	9
238	Higher CD27+CD8+ T Cells Percentages during Suppressive Antiretroviral Therapy Predict Greater Subsequent CD4+ T Cell Recovery in Treated HIV Infection. PLoS ONE, 2013, 8, e84091.	2.5	9
239	Association of Systemic Inflammation With Retinal Vascular Caliber in Patients With AIDS. , 2019, 60, 2218.		9
240	HIV infection is associated with elevated biomarkers of immune activation in Ugandan adults with pneumonia. PLoS ONE, 2019, 14, e0216680.	2.5	9
241	Association Between Bilirubin, Atazanavir, and Cardiovascular Disease Events Among People Living With HIV Across the United States. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, e141-e147.	2.1	9
242	A Randomized Pilot Study Comparing Combination Therapy plus Enfuvirtide versus a Treatment Interruption followed by Combination Therapy plus Enfuvirtide. Antiviral Therapy, 2006, 11, 315-319.	1.0	9
243	Predictive value of CD8+ T cell and CD4/CD8 ratio at two years of successful ART in the risk of AIDS and non-AIDS events. EBioMedicine, 2022, 80, 104072.	6.1	9
244	Pneumoproteins are associated with pulmonary function in HIV-infected persons. PLoS ONE, 2019, 14, e0223263.	2.5	8
245	Timing of Antiretroviral Therapy and Systemic Inflammation in Sub-Saharan Africa: Results From the META Longitudinal Cohort Study. Journal of Infectious Diseases, 2019, 220, 1172-1177.	4.0	8
246	Association of Age-related Macular Degeneration With Mortality in Patients With Acquired Immunodeficiency Syndrome; Role of Systemic Inflammation. American Journal of Ophthalmology, 2019, 199, 230-237.	3.3	8
247	Impact of first-line antiretroviral therapy regimens on the restoration of the CD4/CD8 ratio in the CNICS cohort. Journal of Antimicrobial Chemotherapy, 2020, 75, 1604-1610.	3.0	8
248	Contraceptive use following unintended pregnancy among Ugandan women living with HIV. PLoS ONE, 2018, 13, e0206325.	2.5	7
249	Pre-treatment integrase inhibitor resistance is uncommon in antiretroviral therapy-naive individuals with HIV-1 subtype A1 and D infections in Uganda. Aids, 2021, 35, 1083-1089.	2.2	7
250	Inflammation Investigated as a Source of Pharmacokinetic Variability of Atazanavir in AIDS Clinical Trials Group Protocol A5224s. Antiviral Therapy, 2018, 23, 345-351.	1.0	6
251	Association of Retinal Vascular Caliber and Age-Related Macular Degeneration in Patients With the Acquired Immunodeficiency Syndrome. , 2018, 59, 904.		6
252	CYP2B6Genetic Polymorphisms, Depression, and Viral Suppression in Adults Living with HIV Initiating Efavirenz-Containing Antiretroviral Therapy Regimens in Uganda: Pooled Analysis of Two Prospective Studies. AIDS Research and Human Retroviruses, 2018, 34, 982-992.	1.1	6

#	Article	IF	Citations
253	High Incidence of Intended Partner Pregnancy Among Men Living With HIV in Rural Uganda: Implications for Safer Conception Services. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 497-507.	2.1	6
254	Differential Vpu-Mediated CD4 and Tetherin Downregulation Functions among Major HIV-1 Group M Subtypes. Journal of Virology, 2020, 94, .	3.4	6
255	Changes in Immune Activation During Pregnancy and the Postpartum Period in Treated HIV Infection. Open Forum Infectious Diseases, 2021, 8, ofab245.	0.9	6
256	IFN-Î± blockade during ART-treated SIV infection lowers tissue vDNA, rescues immune function, and improves overall health. JCI Insight, 2022, 7, .	5.0	6
257	Plasma CD16 ⁺ Extracellular Vesicles Associate with Carotid Artery Intima-Media Thickness in HIV ⁺ Adults on Combination Antiretroviral Therapy. MBio, 2022, 13, e0300521.	4.1	6
258	Response: maraviroc intensification and microbial translocation. Blood, 2013, 122, 2283-2284.	1.4	5
259	Higher Body Mass Index Is Associated With Greater Proportions of Effector CD8+ T Cells Expressing CD57 in Women Living With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, e132-e141.	2.1	5
260	The Clinical-Translational Physician-Scientist: Translating Bedside to Bench. Journal of Infectious Diseases, 2018, 218, S12-S15.	4.0	5
261	Association of Gut Intestinal Integrity and Inflammation with Insulin Resistance in Adults Living with HIV in Uganda. AIDS Patient Care and STDs, 2019, 33, 299-307.	2.5	5
262	Internalized stigma, depressive symptoms, and the modifying role of antiretroviral therapy: A cohort study in rural Uganda. SSM Mental Health, 2021, 1, 100034.	1.8	5
263	Association Between Chronic Hepatitis C Virus Infection and Myocardial Infarction Among People Living With HIV in the United States. American Journal of Epidemiology, 2020, 189, 554-563.	3.4	4
264	Shared Mechanisms Govern HIV Transcriptional Suppression in Circulating CD103 ⁺ and Gut CD4 ⁺ T Cells. Journal of Virology, 2020, 95, .	3.4	4
265	Antiretroviral drug class and anaemia risk in the current treatment era among people living with HIV in the USA: a clinical cohort study. BMJ Open, 2020, 10, e031487.	1.9	4
266	Association Between Immunoglobulin E Levels and Kaposi Sarcoma in African Adults With Human Immunodeficiency Virus Infection. Journal of Infectious Diseases, 2021, 223, 101-108.	4.0	4
267	Association of elevated plasma inflammatory biomarker levels with age-related macular degeneration but not cataract in persons with AIDS. Aids, 2022, 36, 177-184.	2.2	4
268	Objective Identification of Cannabis Use Levels in Clinical Populations Is Critical for Detecting Pharmacological Outcomes. Cannabis and Cannabinoid Research, 2022, 7, 852-864.	2.9	4
269	A closer look at hepatitis C clearance in HIV controllers. Aids, 2014, 28, 1241-1242.	2.2	3
270	Second European Round Table on the Future Management of HIV. Journal of Virus Eradication, 2015, 1, 211-220.	0.5	3

#	Article	IF	Citations
271	High-Sequence Diversity and Rapid Virus Turnover Contribute to Higher Rates of Coreceptor Switching in Treatment-Experienced Subjects with HIV-1 Viremia. AIDS Research and Human Retroviruses, 2017, 33, 234-245.	1.1	3
272	Trends in one-year cumulative incidence of death between 2005 and 2013 among patients initiating antiretroviral therapy in Uganda. International Journal of STD and AIDS, 2017, 28, 800-807.	1.1	3
273	HIV DNA decay during antiretroviral therapy. Aids, 2018, 32, 2255-2257.	2.2	3
274	Antiretroviral therapy: stubborn limitations persist. Lancet, The, 2014, 384, 214-216.	13.7	2
275	Cooking Fuel Type and Respiratory Symptoms Among a Cohort of People Living With HIV in Rural Uganda. Chest, 2015, 148, 769A.	0.8	2
276	Non-R5-tropic HIV-1 in subtype A1 and D infections were associated with lower pretherapy CD4+ cell count but not with PI/(N)NRTI therapy outcomes in Mbarara, Uganda. Aids, 2016, 30, 1781-1788.	2.2	2
277	All About the Albumin? Prognostic Capacity of Serum Albumin in Patients With Treated HIV Infection. Journal of Infectious Diseases, 2018, 217, 347-349.	4.0	2
278	Differentiation of Type 1 and Type 2 Myocardial Infarctions Among HIV-Infected Patients Requires Adjudication Due to Overlap in Risk Factors. AIDS Research and Human Retroviruses, 2018, 34, 916-921.	1.1	2
279	Circulating LOXL2 Levels Reflect Severity of Intestinal Fibrosis and GALT CD4+ T Lymphocyte Depletion in Treated HIV Infection. Pathogens and Immunity, 2017, 2, 239.	3.1	2
280	Leaky gut, clotting, and vasculopathy in SIV. Blood, 2012, 120, 1350-1351.	1.4	1
281	Hematologic, Hepatic, Renal, and Lipid Laboratory Monitoring After Initiation of Combination Antiretroviral Therapy in the United States, 2000â€“2010. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 216-220.	2.1	1
282	Safety of Fecal Microbial Transplantation During Treated HIV Infection. American Journal of Gastroenterology, 2015, 110, S578-S579.	0.4	1
283	Reply to Barrett, et al. Clinical Infectious Diseases, 2016, 62, 1468-1469.	5.8	1
284	Brief Report: Should Abacavir Be a First-Line Alternative for Adults With HIV in Sub-Saharan Africa?. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 188-192.	2.1	1
285	Prevalence and Risk Factors for Intimate Partner Violence in Women Living with HIV in Uganda. Open Forum Infectious Diseases, 2017, 4, S663-S663.	0.9	1
286	Alcohol Consumption and Tryptophan Metabolism Among People with HIV Prior to Antiretroviral Therapy Initiation: The Uganda ARCH Cohort Study. Alcohol and Alcoholism, 2021, , .	1.6	1
287	LOXL-2 and TNC-C are markers of liver fibrogenesis in HCV/HIV-, HIV- and HCV-infected patients. Biomarkers in Medicine, 0, , .	1.4	1
288	Multiple substance use, inflammation and cardiac stretch in women living with HIV. Drug and Alcohol Dependence, 2022, 238, 109564.	3.2	1

#	Article	IF	Citations
289	Potential inflammatory consequences in HIV controllers. Retrovirology, 2010, 7, .	2.0	0
290	Persistent HIV-related Stigma in Rural Uganda during a Period of Increasing HIV Incidence. AIDS Research and Human Retroviruses, 2014, 30, A259-A259.	1.1	0
291	Subtype-Specific HIV-1 Adaptation to Host HLA. AIDS Research and Human Retroviruses, 2014, 30, A218-A218.	1.1	0
292	Reply to Cannizzo et al. Journal of Infectious Diseases, 2015, 211, 1514-1515.	4.0	0
293	MicroRNAs. Aids, 2017, 31, 2017-2018.	2.2	0
294	Second European Round Table on the Future Management of HIV: 10-11 October 2014, Barcelona, Spain. Journal of Virus Eradication, 2015, 1, 211-20.	0.5	0
295	A cytotoxic-skewed immune set point predicts low neutralizing antibody levels after Zika virus infection. Cell Reports, 2022, 39, 110815.	6.4	0
296	Attenuated HIV-1 Nef But Not Vpu Function in a Cohort of Rwandan Long-Term Survivors. Frontiers in Virology, 0, 2, .	1.4	0